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Abstract
Background Incremental haemodialysis/haemodiafiltration (HD) may help reduce early mortality rates in patients start-
ing HD. This mixed-method feasibility study aims to test the acceptability, tolerance and safety of a novel incremental HD 
regime, and to study its impact on parameters of patient wellbeing.
Method We aim to enrol 20 patients who will commence HD twice-weekly with progressive increases in duration and 
frequency, achieving conventional treatment times over 15 weeks (incremental group). Participants will be followed-up for 
6 months and will undergo regular tests including urine collections, bio-impedance analyses and quality-of-life question-
naires. Semi-structured interviews will be conducted to explore patients’ prior expectations from HD, their motivations for 
participation and experiences of receiving incremental HD. For comparison of safety and indicators of dialysis adequacy, 
a cohort of 40 matched patients who previously received conventional HD will be constructed from local dialysis records 
(historical controls).
Results Data will be recorded on the numbers screened and proportions consented and completing the study (primary out-
come). Incremental and conventional groups will be compared in terms of differences in blood pressure control, interdialytic 
weight changes, indicators of dialysis adequacy and differences in adverse and serious adverse events. In analyses restricted 
to incremental group, measurements of RRF, fluid load and quality-of-life during follow-up will be compared with baseline 
values. From patient interviews, a narrative description of key themes along with anonymised quotes will be presented.
Conclusion Results from this study will address a significant knowledge gap in the prescription HD therapy and inform the 
development novel future therapy regimens.
Keywords Haemodialysis · Hemodialysis · Incremental HD · Chronic kidney disease · Dialysis
Introduction
In patients with advanced chronic kidney disease (CKD), 
the start of haemodialysis/haemodiafiltration (HD) therapy 
marks the start of a critical transitional period. The abrupt 
changes in patients’ lifestyles, independence and work [1, 2] 
combined with the additional burden of pathophysiological 
changes with the onset of regular dialysis [3–5] worsening 
indices of nutrition and inflammation with advancing CKD 
[6, 7] an increasing burden of co-morbid illnesses [8] and a 
decline in functional status especially in the elderly [9], can 
all lead to higher risk of decompensation in the early days of 
therapy [10, 11]. Mortality rates are highest in the first few 
weeks of treatment [12–14].
Incremental HD, which enables patients to start dialysis 
with smaller doses and gradually building up to traditional 
full dialysis over a longer period, may help reduce some of 
the associated risks early on by allowing patients the time to 
adapt physically and mentally to the new changes [15, 16]. 
Ultimately, a randomised control trial (RCT), testing incre-
mental HD vs. standard care will be needed to definitively 
address if starting HD incrementally reduces mortality in 
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incident dialysis starters [17, 18]. Key uncertainties need 
to be addressed, however, before a definitive RCT can be 
conducted:
A. Wide variations exist in the practice of incremental HD 
worldwide [19, 20]. The optimal design for a suitable 
regimen that is safe, effective and easy to administer 
needs to be fully established through feasibility testing 
before it can be formally tested in an RCT.
B. The level of patient interest and demand for incremen-
tal HD require further exploration. This information is 
needed for planning of resources in the future RCT.
C. The most suitable primary outcome measure for use in 
a future RCT needs further study (this information is 
needed for the sample size calculation)
D. Given the time constraints that come with the delivery 
of each dialysis session and the already high frequency 
of patient exposure to healthcare environment, which 
additional tests should be included in the future RCT to 
help fully understand the impact of incremental HD on 
patient’s health.
To pave the way for a future RCT of incremental HD vs 
standard care, a feasibility study is being conducted which 
aims to establish the acceptability, tolerance and safety of a 
novel incremental HD regime; and to explore the feasibility 
of data collection and follow-up of the participants.
Materials and methods
Study design
A mixed-method study with two key elements:
1. A prospective interventional study, with historical 
matched controls, involving new HD starters; testing the 
feasibility and safety of incremental HD and examining 
the impact of incremental HD on patients’ wellbeing 
(the ‘interventional cohort study’).
2. Semi-structured interviews of study participants to docu-
ment and analyse the experiences of patients receiving 
incremental HD (the ‘interview phase’).
Settings
A large University Teaching Hospital in the UK (Hull Uni-
versity Teaching Hospitals NHS Trust) and its three associ-
ated satellite dialysis units [21].
Participants
Adults with CKD stage 5 (from any cause), commencing 
in-centre maintenance HD therapy for end-stage renal dis-
ease (ESRD) in the out-patient settings. Full eligibility and 
exclusion criteria are presented in Table 1. Pre-dialysis spe-
cialist nephrology input for at least 3 months is essential 
since those without full preparation for dialysis may require 




Participants will be approached at the specialist pre-dialysis 
clinics or the dialysis unit with the participant information 
sheet (PIS). They will be given at least 24 h to consider 
the information. Following this, the investigator will meet 
patients in person to address their questions and obtain written 
informed consent if they show willingness to proceed. They 
will remain in-active in the study, and under follow-up with 
their usual care providers, until the decision is made to start 
HD by their caring physician. The timing of HD initiation 
Table 1  Eligibility criteria for study participants
CKD chronic kidney disease, HD haemodialysis
Inclusion criteria Exclusion criteria
Age ≥ 18
patients with CKD-5 who are about to start planned HD
At least 3 months of prior specialist renal follow-up at the time of starting 
HD
Able to meet all the study requirements
Written signed informed consent
Age < 18
No prior contact with nephrologists for > 3 months
Cross-over into HD from peritoneal dialysis
Currently undergoing HD therapy
Any condition which in the opinion of the investigator makes the 
participant unsuitable for entry into the study
Participation in an interventional study in the preceding 6 weeks
History of myocardial infarction in the preceding 3 months
Inability to provide informed consent
Inability to comply with the study schedule and follow-up
1133Clinical and Experimental Nephrology (2021) 25:1131–1141 
1 3
will be made independently of the study investigators by the 
clinical care teams, based on clinical needs and in consultation 
with patients and their relatives. Clinicians will not be blind to 
patients’ participation in the study; some pre-dialysis CKD-5 
patients may have already signed up for the study prior to 
commencing dialysis. Whether the knowledge of patients’ 
interest in incremental HD influences decisions about the tim-
ing of starting HD is not known. The starting eGFRs will be 
reported for both incremental and control arm patients which 
could help address this current knowledge gap.
Recruitment for control arm (historical controls)
Each participant in the incremental HD arm of the study will 
be matched with 2 patients who had previously received the 
conventional HD treatment (historical controls; matching ratio 
1:2). Participants for the control arm will be identified using 
the local dialysis treatment database. All patients starting 
HD therapy since 2013, the inception date of the database, 
will be included in the searches. Their dialysis treatment data 
(including nursing notes and exceptions), along with details 
of their medical history will be extracted for further analysis 
(see below).
Matching method
Propensity scores matching (PSM) will be undertaken to 
match participants in the incremental HD group with con-
trols. Propensity scores will first be computed using logistic 
regression analysis accounting for the following 14 variables: 
age, C-reactive protein (CRP), serum albumin, vascular access 
type, pre-dialysis serum creatinine, dialysis facility, body 
mass index (BMI), parathyroid hormone levels (PTH), dias-
tolic blood pressure (BP), haemoglobin, systolic BP, vitamin 
K antagonist treatment, history of cardiovascular disease and 
antihypertensive treatment. These variables together predict 
2-year mortality in new dialysis starters with sensitivity and 
specificity of 72% and 69% based on a study by Siga et al. 
[24]. Matching will take place using the nearest neighbour 
method (no pre-specified caliper range) with no replacements.
The intervention (the incremental HD regime)
Participants in the intervention group will receive incremen-
tal HD using a novel approach, starting therapy on twice-
weekly basis with progressive increases in the duration and 
frequency of sessions over 15 weeks, achieving conventional 
treatment times by the end of this period.
The treatment delivered will comprise of a ‘start’ phase, 
representing just the first 2 days of dialysis (this is similar 
to conventional start), followed by 3 incremental phases or 
steps (also see Fig. 2):
• Start (phase 1): (first 2 days of HD): day 1, 2-h HD ses-
sion; day 2, 3-h HD session.
• Phase 2: twice-weekly 2-h long dialysis sessions for 
2 weeks.
• Phase 3: twice-weekly 3-h long dialysis session for 
6 weeks.
• Phase 4: three-times weekly 3-h long session for 6 weeks.
Following this, participants will continue long-term HD 
as per clinical requirements. The regime includes several 
safety elements including frequent fluid status monitoring 
(through clinical examinations and bio-impedance analyses) 
and regular potassium testing. Clinicians and dialysis nurses 
can override the regime at any point if clinically indicated.
The regime tested here has been developed by the study 
investigators (AMH, SB) in consultation with patient groups 
as a pragmatic way of reducing exposure to dialysis during 
the critical early transitional period. At the designing stage, 
patient engagement involved discussions with National Insti-
tute of Health Research (NIHR) patient research ambassa-
dors for renal medicine at our centre and the members of 
Hull Kidney Patients Association (HKPA). In addition, a 
brief questionnaire was given out to 20 current HD patients 
to gauge their opinions on the current proposals. Patient 
feedback was very positive; patients particularly appreci-
ated the focus on maintaining independence at the start of 
HD which they valued highly. HKPA members saw this 
as a much-needed advancement in dialysis therapies and 
felt that patients will be motivated to help. The group gave 
positive suggestions on how to narrow down the process 
of identifying potential participants e.g., by prioritising the 
sub-set of patients who were being referred for vascular 
access procedure (as they are the most likely patients to start 
dialysis soon). In the survey of 20 HD patients, 10 patients 
responded 7 of whom indicated that they would have taken 
part in the study if they had the opportunity.
Sample size
As this is a feasibility study, a formal sample size calcula-
tion has not been performed. The recruitment target is 20 
participants in the active interventional arm and 40 in the 
historical control group (1:2 matching).
Follow‑up
Participants will be followed-up for 6 months from the start 
date of HD therapy (see Fig. 1 above). A total of eight study 
visits will be carried out for each participant as per the sched-
ule presented in supplementary table S1. Participant monitor-
ing, and data collection is more intense in the first 2 weeks.




Data items recorded at baseline include age, gender, 
primary renal disease, names of co-morbid conditions, 
medications list (including the names of anti-hyperten-
sives and diuretics), date of first contact with nephrology 
services, type of vascular access and estimated glomeru-
lar filtration rate (eGFR) based on serum creatinine meas-
urement prior to first dialysis session. Charlson co-mor-
bidity index [25] will be calculated for all participants to 
Fig. 1  Recruitment and follow-up of patients in the intervention and control groups
Fig. 2  Incremental HD regimen used in the study showing the incremental steps
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enable baseline comparison of the burden of co-morbid-
ities. With patients’ permission, we will cross-reference 
medication lists with their primary care records to ensure 
completion.
Weights and blood pressures
Weight and blood pressure (BP) readings will be monitored 
at baseline and then at each subsequent dialysis visit. These 
will be measured pre- and post-dialysis. Inter-dialytic weight 
gain (IDWG) or loss will be recorded. BP readings taken 
during dialysis (intra-dialytic BPs) will also be recorded.
Blood tests
In routine dialysis practice, the drawing of ‘monthly 
bloods’[26] involve regular measurements of full-blood 
count (FBC), serum biochemical profile (BCP) and C-reac-
tive protein (CRP), and 3-monthly measurements of serum 
Ferritin, Transferrin Saturations (TSAT) and Parathyroid 
hormone (PTH) levels. We will utilise these routine tests 
when making selected comparisons between patients in the 
two treatment arms (see outcomes). Bloods samples are 
drawn at the first dialysis session of each calendar month. 
Urea reduction ration (URR) and eKt/Vurea are calculated 
monthly using the pre- and post-dialysis serum urea levels 
[27].
Additional (non-routine) pre-dialysis BCP testing will 
be carried out on days 7, 10 and 14 of dialysis to ensure 
close monitoring of serum potassium levels during the first 
2 weeks of treatment.
Urine collections and estimation of RRF
Serial 24-h interdialytic urine collections will be used to 
monitor RRF. Proportion of patients completing 24-h urine 
collections and urine volumes will be recorded. Renal 
urea clearance (KRU) will be estimated from the rate of 
urea excretion and time-averaged serum urea concentra-
tion change during the collecting interval using method 
described by Obi et al. [28].
Cystatin C levels will be measured pre-dialysis at base-
line, 1, 3 and 6 months. There is controversy on whether 
Cystatin C alone adequately predicts GFR (or RRF) in estab-
lished dialysis patients [29]. Its role in estimating GFR in 
new HD starters remains unexplored and the current study 
presents a unique opportunity to correlate RRF estimates 
from Cystatin C levels and urine collections over the first 
6 months of dialysis.
Bio‑impedance spectroscopy and fluid load
Bio-impedance spectroscopy (BIS) will be performed using 
Body Composition Monitor (Fresenius Medical Care, Ger-
many) [30, 31]. Readings will be taken immediately pre-
dialysis with patients reclined at 30 degrees [32] and elec-
trodes placed on patient’s arm and foot on the same side of 
the body avoiding the vascular access side [33]. N-terminal 
pro-Brain type natriuretic peptide (NT-proBNP) levels will 
be measured at regular intervals to evaluate the impact of 
incremental HD on cardiac load [34, 35].
Quality of life and functional status
Quality of Life will be measured using the Kidney Disease 
Quality of Life Instrument-Short form (KDQOL-SF)™ v1.3 
questionnaire [36] and performance status using the Karnof-
sky performance index [37, 38]. These will be performed 
at baseline and then repeated at 3 and 6 months. All tests, 
except 24-h urine collections, will be completed within the 
designated dialysis slot and will not require additional hos-
pital visits or prolongation of hospital visits.
Safety and adverse events data
There are several safety measures built-in to our incremen-
tal HD program to protect patients from the deleterious 
effects of a rapid decline in RRF around the time of dialy-
sis initiation or when at least three-times weekly dialysis is 
needed from the start. First, we are only recruiting patient 
with planned out-patient dialysis start; this excludes the 
majority of those who develop critical or life-threatening 
issues related to CKD-5. Furthermore, all participants are 
reviewed at the start (see study procedures in supplemen-
tary table S1) to ensure safety before patients commence the 
program. During the program, patients receive regular visits 
from the study team (in the first month, five study related 
checks are undertaken including review by the study medic 
on four occasions). Also, clinicians can change the dialysis 
schedule e.g., offer extra dialysis or to take the patient off 
the program completely at any point during the study; for 
this reason, the mid-week dialysis slot is always kept open 
in case a participant needs additional dialysis. Finally, this a 
short incremental regime lasting just over 3 months; hence, 
a decline in RRF is anticipated and treatment increases are 
pre-emptive in this program.
Information related to adverse events (AEs) and seri-
ous adverse events (SAEs) will be recorded continuously 
throughout the study based on definitions presented in sup-
plementary table S2. Routinely, all dialysis treatments are 
recorded in the local dialysis treatment database and a named 
nurse documents a narrative account of that day’s treatment 
making notes of any significant events. This information 
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will be accessed by the study team and interrogated for AEs 
and SAEs and substantiated with information documented 
elsewhere in patients’ electronic health records. Compliance 
with the programme and adherence (or deviations) to the 
prescription will be monitored.
Intra-dialytic hypotension is common and affects 17% of 
all dialysis sessions [39]. We define IDH in accordance with 
the European Best Practice Guidelines [40] as a sympto-
matic drop in BP during dialysis of ≥ 20 mmHg in systolic 
or ≥ 10 mmHg in mean arterial pressures, requiring nursing 
interventions such as the stopping of ultrafiltration, admin-
istration of saline or moving patients to Trendelenburg posi-
tion. IDH events are recorded in the nursing entries as above 
which will be used as a basis for coding this information.
Primary outcome
The primary outcome of this study is recruitment. We aim to 
recruit 20 patients over 18 months. Data will be kept on the 
number screened, proportion eligible, proportion consenting 
and proportion completing the study.
Justification for primary outcome measure
Ultimately, the aim of this feasibility is to pave the way for 
a future RCT. In the planning of such a RCT, estimates of 
patient recruitment and adherence ratios are necessary as 
it affects resource allocation [41]. We would consider an 
acceptance ratio of ≥ 40% (i.e., the proportion of patients 
enrolled from all those eligible and approached for the 
study) and retention rate of ≥ 70% (i.e., participants complet-
ing the study) to indicate feasibility. Additional HD sessions 
for clinical needs do not affect the retention rate as these 
are considered part of therapy regime along with other key 
safety indicators.
Secondary outcomes
The secondary outcomes of this study are grouped in to fol-
lowing sub-categories:
A. Safety outcomes
To compare key indicators of patient wellbeing in those 
receiving incremental HD and conventional care over the 
6-month follow-up period:
1. Differences in mean pre-dialysis BPs and IDWG (or 
loss)
2. Comparison of pre-dialysis potassium levels, serum 
albumin, PTH, adjusted calcium and phosphate levels.
3. Numbers of AEs and SAEs (based on definitions in 
table S2)
4. Numbers of hospitalisations
5. Numbers and rates of major adverse cardiovascular 
events (the 4p-MACE: a composite of cardiovascular 
deaths, nonfatal myocardial infarctions, nonfatal strokes 
and hospitalisations for unstable angina) [42]
6. Numbers and rates of all-cause mortality
7. Anaemia management: differences in Hb, Ferritin, TSAT 
and doses of IV iron and erythropoietin stimulating 
agent (ESA.)
B. Mechanistic outcomes
To study changes in RRF, fluid load, performance sta-
tus and quality of life over 6 months in patients receiving 
incremental HD (incremental HD group only). All these are 
relative to baseline:
1. Change in RRF using urine volume, KRU and Cystatin 
C levels
2. Change in pre-dialysis fluid load as measured using BIS 
and Ntpro-BNP
3. Change in KDQOL-SF v1.3 scores (including in its sub-
domains)
4. Change in Karnofsky performance index
C. Qualitative outcomes
To explore patients’ experiences of starting HD incremen-
tally and of participating in the current study using semi-
structured interviews—see interview sub-study section.
D. Further feasibility outcomes
To acquire data needed for planning a future RCT:
1. Progression to HD: some patients recruited for the cur-
rent study may not start HD within the study period (the 
timing of onset of dialysis can be unpredictable). Of the 
patients recruited from pre-dialysis clinics, the propor-
tion of patients progressing to receiving incremental 
HD within the study period will be reported. This will 
inform the number of additional participants needed in 
a future RCT and the duration of recruitment period.
2. Completion rates of the non-routine tests namely the 
24-h urine collections, BIS and the KDQOL-SF v1.3 
questionnaire.
Analysis
The findings will be reported in accordance with the Con-
sort Statement for Pilot and Feasibility trials [43]. A con-
sort flowchart showing the number of patients screened, 
approached for participation, consented and those who 
eventually started treatment will be presented.
Patient follow-up period will be split in to the four 
phases of incremental HD regime (see Fig. 2 for phases of 
incremental HD). Details of dialysis treatments delivered 
in each phase to participants in both treatment arms will 
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be expressed in sessions/week (frequency), minutes/week 
(duration), mean monthly URR and median sessional eKt/
Vurea as well as OCM Kt/Vurea. Given that patients in con-
ventional HD group (historical controls) will have had more 
BPs and weight measurements recorded since they were on 
three-times weekly dialysis from the outset, their mid-week 
BP and weight measurements will not be used in computing 
these averages (to avoid regression towards mean). Weights, 
BPs and IDGW will be summarised as means (and SDs) for 
each treatment phase.
Results of routine tests (including Hb, potassium, albu-
min, PTH, adjusted calcium, phosphate), and IV iron and 
ESA doses administered will be summarised (as mean and 
SD or median and inter-quartile range as appropriate) for 
each treatment phase. For patients in incremental HD group, 
urine volumes, KRU, serum Cystatin C levels, pre-dialysis 
overhydration measured through BIS (expressed in millili-
tres), NT-pro-BNP levels will be summarised as means or 
medians as appropriate for each measured time point (base-
line, 1-, 3- and 6-month). Differences in these measurements 
over the follow-up period will be compared to their baseline 
values.
Numbers of deaths from all causes, hospitalisations, the 
4-point major adverse cardiovascular events (4p-MACE: a 
composite of cardiovascular deaths, nonfatal myocardial 
infarctions, nonfatal strokes and hospitalisations for unsta-
ble angina), AEs and SAEs will be reported for both the 
treatment arms.
Formal statistical tests will not be undertaken on sec-
ondary outcomes due to the feasibility design of this study 
(descriptive comparisons will, however, be drawn to exam-
ine findings for potential signals).
Semi‑structured patient interviews
Although there are theoretical advantages in reducing the 
burden of treatment at the start (in incremental HD), gold-
standard evidence for its effectiveness is currently lacking. 
In this context, participants who agree to receive incremental 
HD hold a unique perspective that could aid, and enhance 
the design of a future RCT.
Aims of patient interviews
The key aims of patient interviews are to:
• Capture patients’ prior expectations and understandings 
of starting dialysis treatment
• Elicit their experiences of being approached for partici-
pation in the study
• Understand their motivation for consenting to a trial of a 
new form of dialysis
• Explore patients’ experiences of receiving incremental 
HD
• Gauge participants’ feelings about the regime of 
increased monitoring and tests undertaken as part of 
incremental HD.
Eligibility and recruitment
All participants who have undergone incremental HD (in the 
interventional arm of this study) will be eligible for partici-
pation in this phase of the study. Full eligibility criteria are 
presented in Table 2.
Sample size, interview procedure and analysis
We aim to conduct 10–14 semi-structured interviews (but 
interviews will continue until data saturation is reached) 
[44]. Interviews will be guided by a topic guide (see Table 3) 
designed to capture patient understandings and experiences 
of the intervention and feasibility trial.
All interviews will be conducted either face-to-face whilst 
patients receive their scheduled dialysis or over the internet 
video conferencing. Interviews will be conducted by a single 
researcher and are anticipated to last approximately 1 h.
With participants’ permission, the interviews will be 
recorded on an encrypted laptop or audio recording device 
which will then be transcribed verbatim and managed using 
Nvivo (QSR International, Australia). The transcripts will 
be anonymised, and all names will be replaced by a unique 
identifiers (IDs). Place or staff identifiers within the tran-
scripts will be replaced by unit ID or staff job title. The study 
investigator will use inductive thematic analysis [45] to code 
the interview transcripts and then clustered into themes, 
Table 2  Eligibility criteria for the interview phase of the study
Inclusion criteria Exclusion criteria
Previously received incremental HD in the interventional arm of the 
ENDURE study OR a close relative of someone who has previously 
receive incremental HD in this study
Willing and able to comply with study requirements
Able to give written informed consent
Decline participation in this sub-study
Unable to comply with requirements of the interview process defined in 
this section
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along with anonymised quotes to support the account, will 
be presented in the final report.
Study timeline and future plans
Final analyses will be completed after the 20th partici-
pant (or the last participant recruited within the 18-month 
recruitment period) has completed 6 months follow-up 
(September 2021). Data obtained from this feasibility 
study will be used to design the incremental HD regime 
to be used in a future RCT.
Approvals and registration
This study has been approved by the West of Scotland 
Research Ethics committee-4 (Ref: 19/WS/0019). The 
protocol was registered on clinicaltrials.gov in February 
2020 (NCT04268264).
Table 3  Topic guide for participant interviews
Questions Prompts/clarifications
Looking back to a time when you hadn’t yet started dialysis (i.e. when 
you were still under follow-up at pre-dialysis clinic), what were your 
expectations from dialysis?
Did you have any prior concerns about starting dialysis?
What changes were you expecting dialysis would bring to your lifestyle 
or living arrangements?
What changes were you expecting dialysis would bring to your symp-
toms?
What did you think about being approached for participation in the 
study?
You were approached in …………. (clinical setting), by ………… 
(study personnel), how did you find the experience?
Would you suggest we did anything differently when approaching par-
ticipants for the study in future?
What went well?
What could be improved?
What were the main reasons you said yes to participation in the study? Did you discuss the study with your family?
Did you discuss the study with other health professionals?
Did you have any concerns at the start about participating in the 
study?
Do you think your concerns were adequately addressed?
In hindsight, what do you think we could have been done differently to 
pre-empt and address these concerns?
What are the main things that you got from the study? Do you think there have been any advantages to taking part in the 
study?
Did you experience any problems? How did the problem affect you?
How did the problem affect your family/carers?
In hindsight, what do you think could have been done to avoid this 
problem?
What changes, if any, do you think we need to make to the dialysis 
programme (the ‘incremental dialysis’) itself?
In incremental dialysis, you initially receive treatment twice weekly 
at shorter durations than usual, then your treatment is increased 
gradually over 3 months. I would like to get your thoughts on this 
programme:
When you first started dialysis, did you notice an immediate change in 
how you felt?
Were your symptoms changing with increasing dialysis (for better or 
worse)?
You are now on three-times weekly full-length dialysis. With hindsight, 
did you have any symptoms previously that you think could have been 
because of less frequent dialysis?
The study included several additional procedures and tests that are not 
offered routinely to dialysis patients (these included questionnaires 
and urine collections). How did you find completing those tests?
Anything to report for the 24-h urine collections?
Anything to report for the quality of life questionnaires?
In future studies, should these tests be conducted more often, less often 
or at the same number of times as in this study?
Would you suggest we did anything differently in this study? What changes do you think we need to make to the study overall to 
improve the incremental dialysis regime?
Would you recommend the study to other patients in future? What advice would you give to someone who is about to start dialysis 
treatment and is offered a chance to start dialysis incrementally as part 
of a research study




We have proposed a novel and pragmatic study that sim-
plifies incremental HD by focusing on key elements of 
patient welfare and safety using commonly used measures 
in the care of dialysis patients.
There is currently no agreement on the optimal method 
of implementing incremental HD and the term ‘incremental 
HD’ has been used variably in the past to describe twice-
weekly treatment regimens of different aims and degrees 
of complexity [46–49]. In one version described by Kaja 
Kamal et al. [48], twice-weekly dialysis is administered on 
an ongoing basis as long as RRF is maintained above stdKt/
Vurea > 2. This requires regular RRF measurements through 
timed urine collections and clinicians to react to changes 
in RRF and adjust dialysis prescriptions. Kaja Kamal et al. 
have previously reported that the patients spend a median 
of 9 months receiving incremental HD before transitioning 
to three-times weekly HD [48]. A trial of this regime is cur-
rently underway [50].
Our version of incremental HD is novel as we apply 
twice-weekly HD in a time-limited manner (i.e., the first 
15 weeks of dialysis), which does not require time urine 
collections. In our regime, the key aim is to focus on reduc-
ing the risk of decompensation in the early days of dialy-
sis, while patients are still adapting (and hence aiming to 
reduce the high rates of early mortality) which we hypoth-
esise is related to intensity of dialysis [51]—our approach 
is in contrast to other therapy regimens [19, 46, 52] where 
the primary aim of treatment is to preserve RRF and hence 
influencing medium/long-term outcomes. Our regime is of 
a relatively short duration as we expect RRF to decline sig-
nificantly [53, 54] in first few months of dialysis making 
twice-weekly HD unsustainable.
Other key features that distinguish this version of incre-
mental HD from other solutions proposed previously[46, 50, 
55, 56] include: simplified eligibility criteria (see Table 1) 
that pre-selects out-patient HD starters who are well pre-
pared for dialysis; lack of adequate preparation [22, 57] 
significantly carry worse prognoses and such patients are 
not suitable for incremental HD. Note that previous studies 
have used more complex screening methods such as timed 
urine collections at baseline to select suitable candidates for 
incremental HD, but concerns have been voiced about com-
pletion and accuracy of urine collections in dialysis patients 
[58–60].
As above, we have also bypassed the need for timed urine 
collections in the follow-up period by introducing monitor-
ing measures that focus on key safety parameters (i.e. addi-
tional tests for hyperkalaemia and hydration status). This 
approach opens incremental HD to a wider section of new 
dialysis starters, particularly to the elderly. We pre-specify 
fixed increments in HD treatment times, providing more cer-
tainty to patients and helping dialysis staff with the planning 
of treatments.
The use historical controls is novel in dialysis research. 
A control arm is needed to compare the rates of pre-
defined safety events, and to study the impact of incre-
mental HD on selected patient outcomes. The delivery of 
modern HD therapy is highly regimented and treatment 
records are readily accessible through dedicated dialysis 
databases. This makes the use of historical controls a fea-
sible option, particularly when examining rates of well-
recognised events such as changes in pre-dialysis weights, 
BPs, episodes of hyperkalaemia and details of medical 
interventions. Our strategy hence represents a pragmatic 
approach which also increases the study power when com-
paring selected (the routinely collected) parameters [61, 
62] and ensures timely completion of the study provided 
there is appropriate matching of key confounding attrib-
utes [63].
To our knowledge, this is the first study exploring the 
views of patients receiving incremental HD through rec-
ognised qualitative research methods. Analysing patient 
experiences are an important aspect of gauging future 
demand for incremental HD and forms key part of the fea-
sibility works conducted here. The qualitative methods in 
this study will also aid in achieving a deeper understand-
ing behind some of the quantitative findings (e.g., dropout 
rates) making these findings much more informative.
Future implications
The results from this study will address a significant knowl-
edge gap in the prescription of HD therapy and inform 
the development of novel therapy regimes in future. For 
patients, it would represent a less physiologically challeng-
ing transition into dialysis dependency which could reduce 
rates of early mortality and cardiovascular events, and pos-
sibly improve quality of life. Successful implementation of 
incremental HD could lead to substantial cost-savings to 
healthcare providers by reducing the number of treatments 
required at the start and hospitalisation episodes from com-
plications of HD therapy. We believe that an RCT of incre-
mental HD can be conducted within the next 5 years.
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